Canada's Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi®

Eisai announced that Canada’s Drug Agency (CDA-AMC) issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for eligible patients with mild cognitive impairment in Canada. The positive reimbursement decision should improve expected access and uptake prospects for the therapy (via the BioArctic partnership), supporting incremental revenue visibility.